|
4.12 Biopsies liquides
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
BMS partners again with the company behind Opdivo [Pharmafile]
|
|
|
|
|
|
Back
in 2011, BMS made the decision to partner with Ono on nivolumab, a
choice that would prove financially lucrative to both companies. The
immunotherapy prospect became Opdivo – a treatment that scored $1.2
billion in revenue in the third quarter alone.
|
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2 Pharma
|
|
|
Novartis announces Oncology head to retire [Novartis]
|
|
|
|
|
|
"I'd
like to thank Bruno Strigini for his contributions and achievements. He
has navigated the business unit through the Gleevec® patent expiration
and has led the successful integration of the GSK Oncology Product
Portfolio acquired in 2015. I wish him the best for his future."
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
6.1 Observation
|
|
|
Prior Cancers Common in Patients Newly Diagnosed with Cancer [NCI]
|
|
|
|
|
|
The
University of Texas Southwestern researchers pulled data from NCI’s
Surveillance, Epidemiology, and End Results cancer registries for
740,990 persons newly diagnosed with cancer between January 2009 through
December 2013. Overall, they found that 18.4% of newly diagnosed
patients had a prior history of cancer.
|
|
|
|
|
|
|
6.13 Soins palliatifs
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|
|